Archive of SID Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia

Introduction: Imatinib Mesylate is a selective inhibitor of TK and is considered now to be the frontline therapeutic agent during the chronic phase of CML. We have evaluated the efficacy of it on children with chronic-phase of CML. Patients and Methods: In a clinical trial study over the past 3 years, 14 patients (8 females and 6 males, 2.5-14 years old) were admitted with a diagnosis of CML. Seven patients who were in the early chronic-phase and seven who were in the late chronic-phase suffered from hematological relapse while being treated with conventional therapy. All of them had positive BCR-ABL in peripheral blood and bone marrow. Glivec was given as an oral dose of 300mg/m 2 /d. Then, regular monitoring was done for hematological and cytogenetic